Supernus Pharma (SUPN) Misses Q1 EPS by 58c, Beats on Revenue

Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of ($0.21), $0.58 worse than the analyst estimate of $0.37. Revenue for the quarter came in at $149.8 million versus the consensus estimate of $146.9 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Hamilton Beach Brands Holding Co. (HBB) Declares $0.125 Quarterly Dividend; 1.5% Yield
• Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates